
Browsing restrictions can be lifted for a fee.
-
Churchill capital corp xi
0.10%
Avg of Sector
0.34%
S&P500
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
No related data records
The most recent financial report for Churchill capital corp xi (CCXI) covers the period of 2022Q2 and was published on 2022/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CCXI's short-term business performance and financial health. For the latest updates on CCXI's earnings releases, visit this page regularly.
According to the latest financial report, Churchill capital corp xi (CCXI) reported an Operating Profit of -31.57M with an Operating Margin of -268.42% this period, representing a growth of 18.49% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Churchill capital corp xi (CCXI) announced revenue of 11.76M, with a Year-Over-Year growth rate of 548.81%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Churchill capital corp xi (CCXI) had total debt of 68.97M, with a debt ratio of 0.16. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Churchill capital corp xi (CCXI) held Total Cash and Cash Equivalents of 44.4M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Churchill capital corp xi (CCXI) did not achieve the “three margins increasing” benchmark, with a gross margin of 93.2%%, operating margin of -268.42%%, and net margin of -269.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CCXI's profit trajectory and future growth potential.
According to the past four quarterly reports, Churchill capital corp xi (CCXI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Churchill capital corp xi (CCXI)'s Free Cash Flow (FCF) for the period is -26.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 25.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Churchill capital corp xi (CCXI) has a Price-To-Earnings (PE) ratio of -27.28 and a Price/Earnings-To-Growth (PEG) ratio of 0.75. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.